| A SARS-CoV-2 protein interaction map reveals targets for drug repurposing DE Gordon, GM Jang, M Bouhaddou, J Xu, K Obernier, KM White, ... Nature 583 (7816), 459-468, 2020 | 4500 | 2020 |
| Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment N Jura, NF Endres, K Engel, S Deindl, R Das, MH Lamers, DE Wemmer, ... Cell 137 (7), 1293-1307, 2009 | 684 | 2009 |
| Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms DE Gordon, J Hiatt, M Bouhaddou, VV Rezelj, S Ulferts, H Braberg, ... Science 370 (6521), eabe9403, 2020 | 641 | 2020 |
| Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface X Zhang, KA Pickin, R Bose, N Jura, PA Cole, J Kuriyan Nature 450 (7170), 741-744, 2007 | 397 | 2007 |
| Evolution of enhanced innate immune evasion by SARS-CoV-2 LG Thorne, M Bouhaddou, AK Reuschl, L Zuliani-Alvarez, B Polacco, ... Nature 602 (7897), 487-495, 2022 | 390 | 2022 |
| Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3 N Jura, Y Shan, X Cao, DE Shaw, J Kuriyan Proceedings of the National Academy of Sciences 106 (51), 21608-21613, 2009 | 382 | 2009 |
| Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms N Jura, X Zhang, NF Endres, MA Seeliger, T Schindler, J Kuriyan Molecular cell 42 (1), 9-22, 2011 | 337 | 2011 |
| A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties JM Murphy, Q Zhang, SN Young, ML Reese, FP Bailey, PA Eyers, ... Biochemical Journal 457 (2), 323-334, 2014 | 280 | 2014 |
| EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma QW Fan, CK Cheng, WC Gustafson, E Charron, P Zipper, RA Wong, ... Cancer cell 24 (4), 438-449, 2013 | 279 | 2013 |
| Differential modification of Ras proteins by ubiquitination N Jura, E Scotto-Lavino, A Sobczyk, D Bar-Sagi Molecular cell 21 (5), 679-687, 2006 | 242 | 2006 |
| Structural basis for the non-catalytic functions of protein kinases JE Kung, N Jura Structure 24 (1), 7-24, 2016 | 164 | 2016 |
| hSpry2 is targeted to the ubiquitin-dependent proteasome pathway by c-Cbl AB Hall, N Jura, J DaSilva, YJ Jang, D Gong, D Bar-Sagi Current biology 13 (4), 308-314, 2003 | 160 | 2003 |
| Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility EW Stawiski, D Diwanji, K Suryamohan, R Gupta, FA Fellouse, ... BioRxiv, 2020.04. 07.024752, 2020 | 150 | 2020 |
| Receptor tyrosine kinase activation: From the ligand perspective R Trenker, N Jura Current opinion in cell biology 63, 174-185, 2020 | 148 | 2020 |
| Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2 K Suryamohan, D Diwanji, EW Stawiski, R Gupta, S Miersch, J Liu, ... Communications biology 4 (1), 475, 2021 | 145 | 2021 |
| Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking M Schuller, GJ Correy, S Gahbauer, D Fearon, T Wu, RE Díaz, ID Young, ... Science advances 7 (16), eabf8711, 2021 | 139 | 2021 |
| Actionable activating oncogenic ERBB2/HER2 transmembrane and juxtamembrane domain mutations KB Pahuja, TT Nguyen, BS Jaiswal, K Prabhash, TM Thaker, K Senger, ... Cancer cell 34 (5), 792-806. e5, 2018 | 130 | 2018 |
| Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations P Littlefield, L Liu, V Mysore, Y Shan, DE Shaw, N Jura Science signaling 7 (354), ra114-ra114, 2014 | 128 | 2014 |
| A mouse model of hereditary pancreatitis generated by transgenic expression of R122H trypsinogen H Archer, N Jura, J Keller, M Jacobson, D Bar–Sagi Gastroenterology 131 (6), 1844-1855, 2006 | 127 | 2006 |
| Prospects for pharmacological targeting of pseudokinases JE Kung, N Jura Nature Reviews Drug Discovery 18 (7), 501-526, 2019 | 123 | 2019 |
